Fractyl Health, Inc. (NASDAQ:GUTS) Shares Sold by Citadel Advisors LLC

Citadel Advisors LLC lessened its stake in Fractyl Health, Inc. (NASDAQ:GUTS) by 11.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 732,009 shares of the company’s stock after selling 90,821 shares during the period. Citadel Advisors LLC owned 1.52% of Fractyl Health worth $1,508,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Rhumbline Advisers boosted its stake in Fractyl Health by 73.1% during the 4th quarter. Rhumbline Advisers now owns 25,626 shares of the company’s stock worth $53,000 after purchasing an additional 10,826 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Fractyl Health during the fourth quarter worth about $34,000. Norges Bank purchased a new position in shares of Fractyl Health during the fourth quarter worth about $206,000. Bank of New York Mellon Corp grew its holdings in shares of Fractyl Health by 27.3% during the fourth quarter. Bank of New York Mellon Corp now owns 41,448 shares of the company’s stock worth $85,000 after buying an additional 8,886 shares during the last quarter. Finally, HighTower Advisors LLC increased its position in Fractyl Health by 72.8% in the 4th quarter. HighTower Advisors LLC now owns 25,921 shares of the company’s stock valued at $53,000 after acquiring an additional 10,921 shares during the period.

Fractyl Health Trading Up 2.6%

NASDAQ GUTS opened at $1.80 on Monday. The company has a quick ratio of 5.57, a current ratio of 5.58 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $88.16 million, a P/E ratio of -0.15 and a beta of 0.10. Fractyl Health, Inc. has a 52-week low of $0.87 and a 52-week high of $7.43. The firm has a 50-day moving average price of $1.35 and a 200 day moving average price of $1.69.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Tuesday, May 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.49). Equities research analysts expect that Fractyl Health, Inc. will post -1.61 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Canaccord Genuity Group assumed coverage on Fractyl Health in a research report on Tuesday, April 15th. They set a “buy” rating and a $12.00 price objective for the company. Morgan Stanley decreased their price target on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a report on Monday, February 3rd.

Fractyl Health Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.